Editor's ChoiceFOCIS HIGHLIGHTS

The depth of mutational agony and the exuberance of tumoral T cell ecstasy predict checkpoint salvation

See allHide authors and affiliations

Science Immunology  07 Dec 2018:
Vol. 3, Issue 30, eaav9722
DOI: 10.1126/sciimmunol.aav9722

Abstract

Genomic biomarkers will help to elucidate which cancer patients will benefit from PD-1 blockade immunotherapy.

View Full Text